pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of subjects (n=341, n (%) or mean ±SD)

Variables Medication adherence p-value

Adherence group (n=232) Once/month (n=67) Once/2weeks (n=18) More than once a week (n=24)
Depressive symptom
Normal 154 (66.4) 39 (58.2) 7 (38.9) 13 (54.2) 0.072
Depression 78 (33.6) 28 (41.8) 11 (61.1) 11 (45.8)
Anxiety
Normal 184 (79.3) 56 (83.6) 11 (61.1) 19 (79.2) 0.236
Anxiety 48 (20.7) 11 (16.4) 7 (38.9) 5 (20.8)
Gender
Male 221 (95.3) 65 (97.0) 15 (83.3) 21 (87.5) 0.056
Female 11 (4.7) 2 (3.0) 3 (16.7)) 3 (12.5)
Age 41.1±12.6 38.4±11.6 38.4±9.7 37.5±10.8 0.215
Marital status
Single 139 (59.9) 41 (61.2) 14 (77.8) 17 (70.8) 0.274
Married 71 (30.6) 18 (26.9) 2 (11.1) 3(12.5)
Divorced etc. 22 (9.5) 8 (11.9) 2 (11.1) 4 (16.7)
Transmission route
Homosexual 83 (35.8) 23 (34.4) 5 (27.8) 8 (33.3) 0.197
Heterosexual 104 (44.8) 32 (31.3) 7 (38.9) 11 (45.8)
Bisexual 45(19.4) 23 (34.3) 6 (33.3) 5 (20.9)
Health related factor
Smoke and drink 55 (23.7) 23 (34.3) 8 (44.4) 10 (41.7) 0.091
Smoke or drink 113 (48.7) 31 (47.3) 6 (33.3) 12 (50.0)
Non-smoke and non-drink 64 (27.6) 13 (19.4) 4 (22.3) 2 (8.3)
ART regimen group*
Non-booster PI 15 (6.5) 7 (10.5) 5 (27.7) 2 (8.4) 0.073
Boosted PI 94 (40.5) 30 (44.8) 7 (38.9) 12 (50.0)
NNRTI 53 (22.8) 20 (29.8) 3 (16.7) 5 (20.8)
INI 70 (30.2) 10 (14.9) 3 (16.7) 5 (20.8)

*ART regimen group: antiretroviral treatment group, Non-boosted PI: non-boosted Protease inhibitors, boosted PI: boosted protease inhibitors, NNRTI: Non-nucleoside reverse transcriptase inhibitors, INI: integrase inhibitors

Korean J Clin Pharm 2023;33:254-60 https://doi.org/10.24304/kjcp.2023.33.4.254
© 2023 Korean J Clin Pharm